CD20 Inhibitors and Bisfluoroalkyl-1,4-Benzodiazepinone Compounds - EP3790553A1
Summary
EPO published patent application EP3790553A1 for compositions comprising CD20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use, filed by Ayala Pharmaceuticals Inc. The application names Roni MAMLUK as inventor and covers pharmaceutical compositions for therapeutic use, with A61P 35/00 classification indicating oncology applications. The designated states include all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 36 changes logged to date.
What changed
EPO published patent application EP3790553A1 for pharmaceutical compositions comprising CD20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds. The application, filed by Ayala Pharmaceuticals Inc. with inventor Roni MAMLUK, covers methods of use for these compositions. The A61P 35/00 IPC classification indicates oncology as the intended therapeutic area. Designated states cover all EPC contracting states across Europe.
Competitors developing CD20-targeted therapies or benzodiazepinone-based pharmaceuticals should review this published application for potential freedom-to-operate considerations or opposition opportunities during the nine-month opposition period following grant.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS COMPRISING CD20 INHIBITORS AND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF
Publication EP3790553A1 Kind: A1 Apr 15, 2026
Applicants
Ayala Pharmaceuticals Inc.
Inventors
MAMLUK, Roni
IPC Classifications
A61K 31/5513 20060101AFI20220318BHEP A61K 39/395 20060101ALI20220318BHEP A61K 31/661 20060101ALI20220318BHEP A61K 35/17 20150101ALI20220318BHEP A61P 35/00 20060101ALI20220318BHEP A61K 45/06 20060101ALI20220318BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.